Kairos Pharma, LTD 8-K filings

Kairos Pharma has entered into an agreement with PreCheck Health Services to develop biomarkers for their cancer therapy, ENV105, aimed at improving patient selection and treatment monitoring in lung and prostate cancer clinical trials.

Kairos Pharma, a clinical-stage biopharmaceutical company, has successfully completed its initial public offering, raising $6.2 million before expenses.